
A Proposal To Develop A Self-Regulating Hydromorphone Tablet To Deter Excess OralAward last edited on: 10/27/14
Sponsored Program
SBIRAwarding Agency
NIH : NIDATotal Award Amount
$299,694Award Phase
1Solicitation Topic Code
-----Principal Investigator
Albert W BrzeczkoCompany Information
Acura Pharmaceuticals Inc
616 N North Court Suite 120
Palatine, IL 60067
Palatine, IL 60067
(847) 705-7709 |
info@acurapharm.com |
www.acurapharm.com |
Location: Multiple
Congr. District: 05
County: Cook
Congr. District: 05
County: Cook
Phase I
Contract Number: 1R44DA037921-01Start Date: 9/1/14 Completed: 2/28/15
Phase I year
2014Phase I Amount
$299,694Thesaurus Terms:
Absorption;Active Control;Address;Alprazolam;Antacids;Area;Base;Benzodiazepines;Biological Assay;Biological Availability;Buffers;Characteristics;Clinical;Commercialization;Complex;Consumption;Cost;Data;Deglutition;Design;Development;Dose;Drug Formulations;Drug Kinetics;Drug Seeking Behavior;Environment;Euphoria;Exhibits;Fasting;Fda Approved;Feeding;Feeling;Food;Gastric Acid;Goals;Health;Healthy Volunteer;Human;Hydromorphone;In Vitro;In Vitro Testing;In Vivo;Informal Social Control;Intravenous;Laboratories;Marketing;Medical;Medical Specialties;Methods;Opioid;Opioid Abuse;Opioid Analgesics;Opioid Misuse;Oral;Overdose;Oxycodone;Particle;Pharmaceutical Preparations;Pharmacodynamics;Pharmacologic Substance;Phase;Placebo Control;Prescription Opioid;Prescription Opioid Abuse;Product Approvals;Prototype;Relative (Related Person);Research;Route;Safety;Stem;Stomach;Tablet Formulation;Tablets;Technology;Testing;Therapeutic Equivalency;Time;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00